Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Acq. announced
Appointed director
|
|
Arbutus Biopharma Corp (ABUS)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/11/2023 |
8-K
| Quarterly results |
| 08/03/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/03/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/03/2023 |
8-K
| Quarterly results|
Docs:
|
"Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update Regulatory approval received in New Zealand to advance AB-101, our oral PD-L1 inhibitor, into a Phase 1 clinical trial with dosing to begin this quarter AB-729 , in combination with pegylated interferon alfa-2a, in a Phase 2a clinical trial, was generally well tolerated and appears to result in continued HBsAg declines in some patients First patient dosed in additional arm of Phase 2a clinical trial combining imdusiran, VTP-300, NA therapy and nivolumab – advancing towards goal of further stimulating host HBV-associated immunity Cash runway into the first quarter of 2025 Conference Call and Webcast Today at 8:45 AM ET WARMINSTER, Pa., Aug. 03, 2023 -- Arbutus Biopharma Corporation , a clinical-stage biopharmaceutica...",
"Corporate Presentation" |
|
| 07/13/2023 |
4
| Rewolinski Melissa (Director) has filed a Form 4 on Arbutus Biopharma Corp|
Txns:
| Granted 110,000 options to buy
@ $0 |
|
| 07/13/2023 |
3
| Rewolinski Melissa (Director) has filed a Form 3 on Arbutus Biopharma Corp |
| 07/12/2023 |
4
| Sims Karen (Chief Medical Officer) has filed a Form 4 on Arbutus Biopharma Corp|
Txns:
| Granted 153,640 options to buy
@ $2.26, valued at
$347.2k
|
|
| 07/12/2023 |
3
| Sims Karen (Chief Medical Officer) has filed a Form 3 on Arbutus Biopharma Corp |
| 07/12/2023 |
4
| Naftzger J. Christopher (General Counsel and CCO) has filed a Form 4 on Arbutus Biopharma Corp|
Txns:
| Granted 500,000 options to buy
@ $0 |
|
| 07/12/2023 |
3
| Naftzger J. Christopher (General Counsel and CCO) has filed a Form 3 on Arbutus Biopharma Corp |
| 07/12/2023 |
8-K
| Quarterly results |
| 07/10/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 06/07/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 05/30/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/26/2023 |
4
| HENRIQUES RICHARD C JR (Director) has filed a Form 4 on Arbutus Biopharma Corp|
Txns:
| Granted 55,000 options to buy
@ $0 |
|
| 05/26/2023 |
4
| BURGESS DANIEL D (Director) has filed a Form 4 on Arbutus Biopharma Corp|
Txns:
| Granted 55,000 options to buy
@ $0 |
|
| 05/26/2023 |
4
| MANCHESTER KEITH S (Director) has filed a Form 4 on Arbutus Biopharma Corp|
Txns:
| Granted 55,000 options to buy
@ $0 |
|
| 05/26/2023 |
4
| Torti Frank (Director) has filed a Form 4 on Arbutus Biopharma Corp|
Txns:
| Granted 55,000 options to buy
@ $0 |
|
| 05/26/2023 |
4
| Meyers James R (Director) has filed a Form 4 on Arbutus Biopharma Corp|
Txns:
| Granted 55,000 options to buy
@ $0 |
|
| 05/04/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/04/2023 |
8-K
| Quarterly results |
| 04/27/2023 |
8-K
| Quarterly results |
| 04/25/2023 |
8-K
| Quarterly results |
| 04/18/2023 |
8-K
| Quarterly results |
| 04/04/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 03/16/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Arbutus Doses First Subject in Phase 1 Clinical Trial with its Oral RNA Destabilizer, AB-161 Initial data expected in the second half of 2023 WARMINSTER, Pa., March 16, 2023 -- Arbutus Biopharma Corporation , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the first subject has been dosed in the Phase 1 clinical trial evaluating the safety, tolerability, and pharmacokinetics of AB-161, Arbutus’ oral RNA destabilizer. AB-161 is being developed for use in an all-oral combination regimen to potentially provide a functional cure for patients with hepatitis B virus . “We are pleased to move AB-161 into Phase 1 clinical development,” said William Collier, President and C..." |
|
| 03/02/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/02/2023 |
8-K
| Quarterly results|
Docs:
|
"Arbutus Reports Fourth Quarter and Year End 2022 Financial Results and Corporate Update Significant progress made advancing proprietary programs in chronic HBV and Coronavirus AB-729 data from multiple Phase 2a combination clinical trials expected in 2023 Initial Phase 1 data for oral PD-L1, AB-101, and oral RNA Destabilizer, AB-161, expected in the second half of 2023 Initiate Phase 1 clinical trial for oral M pro coronavirus candidate, AB-343, expected in the second half of 2023 Strengthened financial position – cash runway into Q4 2024 Conference Call and Webcast Today at 8:45 AM ET WARMINSTER, Pa., March 02, 2023 -- Arbutus Biopharma Corporation , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific vi...",
"Corporate Presentation" |
|
| 02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/03/2023 |
SC 13G
| BlackRock Inc. reports a 5.6% stake in Arbutus Biopharma Corp |
|
|
|